315 related articles for article (PubMed ID: 15638294)
1. Cabergoline therapy of growth hormone & growth hormone/prolactin secreting pituitary tumors.
Freda PU; Reyes CM; Nuruzzaman AT; Sundeen RE; Khandji AG; Post KD
Pituitary; 2004; 7(1):21-30. PubMed ID: 15638294
[TBL] [Abstract][Full Text] [Related]
2. Cabergoline in the treatment of acromegaly: a study in 64 patients.
Abs R; Verhelst J; Maiter D; Van Acker K; Nobels F; Coolens JL; Mahler C; Beckers A
J Clin Endocrinol Metab; 1998 Feb; 83(2):374-8. PubMed ID: 9467544
[TBL] [Abstract][Full Text] [Related]
3. In vivo and in vitro effects of octreotide, quinagolide and cabergoline in four hyperprolactinaemic acromegalics: correlation with somatostatin and dopamine D2 receptor scintigraphy.
Ferone D; Pivonello R; Lastoria S; Faggiano A; Del Basso de Caro ML; Cappabianca P; Lombardi G; Colao A
Clin Endocrinol (Oxf); 2001 Apr; 54(4):469-77. PubMed ID: 11318782
[TBL] [Abstract][Full Text] [Related]
4. Place of cabergoline in acromegaly: a meta-analysis.
Sandret L; Maison P; Chanson P
J Clin Endocrinol Metab; 2011 May; 96(5):1327-35. PubMed ID: 21325455
[TBL] [Abstract][Full Text] [Related]
5. Bromocriptine, a dopamine agonist, increases growth hormone secretion in a patient with acromegaly.
Arihara Z; Sakurai K; Yamashita R; Niitsuma S; Ueno T; Yamamura N; Yamada S; Inoshita N; Takahashi K
Tohoku J Exp Med; 2014 Oct; 234(2):129-35. PubMed ID: 25253414
[TBL] [Abstract][Full Text] [Related]
6. Clinical use of cabergoline as primary and adjunctive treatment for acromegaly.
Moyes VJ; Metcalfe KA; Drake WM
Eur J Endocrinol; 2008 Nov; 159(5):541-5. PubMed ID: 18708434
[TBL] [Abstract][Full Text] [Related]
7. Recovery of growth hormone secretion following cabergoline treatment of macroprolactinomas.
George LD; Nicolau N; Scanlon MF; Davies JS
Clin Endocrinol (Oxf); 2000 Nov; 53(5):595-9. PubMed ID: 11106920
[TBL] [Abstract][Full Text] [Related]
8. Cabergoline in acromegaly.
Kuhn E; Chanson P
Pituitary; 2017 Feb; 20(1):121-128. PubMed ID: 28025719
[TBL] [Abstract][Full Text] [Related]
9. Positive prolactin response to bromocriptine in 2 patients with cabergoline-resistant prolactinomas.
Iyer P; Molitch ME
Endocr Pract; 2011; 17(3):e55-8. PubMed ID: 21324816
[TBL] [Abstract][Full Text] [Related]
10. Characterization of gsp-mediated growth hormone excess in the context of McCune-Albright syndrome.
Akintoye SO; Chebli C; Booher S; Feuillan P; Kushner H; Leroith D; Cherman N; Bianco P; Wientroub S; Robey PG; Collins MT
J Clin Endocrinol Metab; 2002 Nov; 87(11):5104-12. PubMed ID: 12414879
[TBL] [Abstract][Full Text] [Related]
11. Cabergoline treatment of acromegaly: a preliminary dose finding study.
Jackson SN; Fowler J; Howlett TA
Clin Endocrinol (Oxf); 1997 Jun; 46(6):745-9. PubMed ID: 9274706
[TBL] [Abstract][Full Text] [Related]
12. Octreotide as primary therapy for acromegaly.
Newman CB; Melmed S; George A; Torigian D; Duhaney M; Snyder P; Young W; Klibanski A; Molitch ME; Gagel R; Sheeler L; Cook D; Malarkey W; Jackson I; Vance ML; Barkan A; Frohman L; Kleinberg DL
J Clin Endocrinol Metab; 1998 Sep; 83(9):3034-40. PubMed ID: 9745397
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of combined octreotide and cabergoline treatment in patients with acromegaly: a retrospective clinical study and review of the literature.
Suda K; Inoshita N; Iguchi G; Fukuoka H; Takahashi M; Nishizawa H; Yamamoto M; Yamada S; Takahashi Y
Endocr J; 2013; 60(4):507-15. PubMed ID: 23291436
[TBL] [Abstract][Full Text] [Related]
14. Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status.
Cozzi R; Attanasio R; Lodrini S; Lasio G
Clin Endocrinol (Oxf); 2004 Aug; 61(2):209-15. PubMed ID: 15272916
[TBL] [Abstract][Full Text] [Related]
15. Results of a two-year treatment with slow release lanreotide in acromegaly.
Cannavò S; Squadrito S; Curtò L; Almoto B; Vieni A; Trimarchi F
Horm Metab Res; 2000 Jun; 32(6):224-9. PubMed ID: 10898551
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of slow-release lanreotide in previously operated and untreated patients with GH-secreting pituitary macroadenoma.
Cannavò S; Squadrito S; Curtò L; Almoto B; Trimarchi F
Horm Metab Res; 2001 Oct; 33(10):618-24. PubMed ID: 11607883
[TBL] [Abstract][Full Text] [Related]
17. Substantial shrinkage of adenomas cosecreting growth hormone and prolactin with use of cabergoline therapy.
Vilar L; Czepielewsk MA; Naves LA; Rollin GA; Casulari LA; Coelho CE
Endocr Pract; 2007; 13(4):396-402. PubMed ID: 17669717
[TBL] [Abstract][Full Text] [Related]
18. Cabergoline in acromegaly: a renewed role for dopamine agonist treatment?
Cozzi R; Attanasio R; Barausse M; Dallabonzana D; Orlandi P; Da Re N; Branca V; Oppizzi G; Gelli D
Eur J Endocrinol; 1998 Nov; 139(5):516-21. PubMed ID: 9849816
[TBL] [Abstract][Full Text] [Related]
19. Remission of acromegaly following long-term therapy with cabergoline: report of two cases.
Verhelst JA; Abrams PJ; Abs R
Pituitary; 2008; 11(1):103-7. PubMed ID: 17530416
[TBL] [Abstract][Full Text] [Related]
20. Role of the addition of cabergoline to the management of acromegalic patients resistant to longterm treatment with octreotide LAR.
Vilar L; Azevedo MF; Naves LA; Casulari LA; Albuquerque JL; Montenegro RM; Montenegro RM; Figueiredo P; Nascimento GC; Faria MS
Pituitary; 2011 Jun; 14(2):148-56. PubMed ID: 21104199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
